

Votrient® – Prior Authorization Request (For Maryland Only)

Send completed form to: Case Review Unit CVS/caremark Specialty Programs Fax: 866-249-6155

CVS/caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS/caremark toll-free at 866-249-6155.** If you have questions regarding the prior authorization, please contact CVS/caremark at **866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 800-237-2767.

Patient Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

1. What drug is being prescribed? **Votrient®** **Other** _____
2. What is the patient's diagnosis?
 - Renal cell carcinoma
 - Soft tissue sarcoma
 - Uterine sarcoma
 - Thyroid sarcoma
 - Other _____
3. What is the ICD code? _____
4. Would the prescriber like to request an override of the step therapy requirement? Yes No If no, skip to #7.
5. Has the member received the medication through a pharmacy or medical benefit within the past 180 days? Yes No
ACTION REQUIRED: Please provide documentation to substantiate the member had a prescription paid for within the past 180 days (i.e., PBM medication history, pharmacy receipt, EOB etc.)
6. Is the medication effective in treating the member's condition? Yes No
 Continue to #7 and complete this form in its entirety.
7. Will **Votrient®** be used as a single agent? Yes No

Complete the following section based on the patient's diagnosis.

Section A: Renal Cell Carcinoma

8. Is the disease relapsed or medically unresectable? Yes No

Section B: Soft Tissue Sarcoma

9. Does the disease express ANY of the following histologies? **No further questions unless "Other" was selected.**
- Adipocytic sarcoma Gastrointestinal stromal tumor Pleomorphic rhabdomyosarcoma
 - Angiosarcoma Other _____
10. Is the sarcoma retroperitoneal or intra-abdominal? *If Yes, skip to #12* Yes No
11. Is the sarcoma located in an extremity or in the superficial trunk? Yes No
12. Is the disease unresectable, progressive, or recurrent? Yes No

Section C: Uterine Sarcoma

13. What is the stage of the disease? I II III IV
14. *If patient has stage I*, Is the disease medially inoperable? Yes No

Section D: Thyroid Sarcoma

15. Is the disease unresectable or metastatic? Yes No
16. Is the disease progressive or symptomatic? Yes No
17. Is the disease radio-iodine refractory? Yes No
18. Is Nexavar® (sorafenib) an appropriate option for this patient? Yes No
19. Does the disease express ANY of the following histologies?
 Papillary Hürthle cell Follicular Other _____

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS/caremark or the benefit plan sponsor.

X _____
Prescriber or Authorized Signature **Date: (mm/dd/yy)**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Vidaza SGM 1/2014